期刊文献+

Aquaporin1在胶质瘤中的表达及其临床意义

Aquaporin1 expression in glioma patients and its potential function in glioma progression
下载PDF
导出
摘要 目的:探讨水通道蛋白1(aquaporin1,AQP1)在胶质瘤中的表达情况及其与临床病理参数、预后的关系,观察AQP1对恶性胶质瘤细胞增殖、侵袭的影响。方法:采用免疫组织化学染色法检测135例肿瘤组织中AQP1的表达情况,分析AQP1与胶质瘤临床病理特征的关系,使用临床资料完整的103例胶质瘤标本分析AQP1与生存的关系。将AQP1连接至慢病毒表达质粒载体后感染恶性胶质瘤LN229细胞,Western blot检测目的蛋白的表达;MTT实验和Transwell小室实验分别检测胶质瘤细胞的增殖和侵袭能力。结果:AQP1的表达水平与胶质瘤的病理分级呈正相关,AQP1高表达与患者预后差相关(P<0.05)。过表达AQP1可增强胶质瘤细胞的增殖、侵袭能力(P<0.05)。结论:AQP1表达与胶质瘤进展密切相关,其表达上调可显著增强胶质瘤细胞的增殖和侵袭能力,有望为胶质瘤的临床检测及治疗提供新思路。 Objective:To explore the expression of aquaporin1 (AQP1) in human glioma tissues and its relationship with the clini-copathological parameters and prognosis of this tumor. This study also observed the function of AQP1 in the proliferation and invasion of LN229 glioblastoma cells. Methods:The expression of AQP1 in 135 cases of glioma was detected by immunohistochemical meth-od, and the correlation between AQP1 and pathological features of glioma was analyzed. The relationship of AQP1 with survival was al-so investigated using 103 specimens with complete clinical data. AQP1 was successfully transfected into LN229 cells with lentiviral vector, and the expression of AQP1 protein was tested by Western blot. Cell proliferation was detected by using methyl thiazolyl tetrazo-lium assay, whereas cell invasion was determined by Transwell assay. Results:The expression of AQP1 was positively correlated with pathological grading. High AQP1 expression was associated with poor prognosis (P〈0.05). Moreover, the overexpression of AQP1 can significantly increase the proliferation and invasion of LN229 cells (P〈0.05). Conclusion:AQP1 is closely associated with the progres-sion of glioma. Upregulation of the AQP1 expression promoted the proliferation and metastasis of glioma cells. These findings indicat-ed that AQP1 can function as a therapeutic target for glioma in future research.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2015年第10期493-498,共6页 Chinese Journal of Clinical Oncology
关键词 胶质瘤 水通道蛋白1 增殖 侵袭 生存 glioma proliferation invasion survival
  • 相关文献

参考文献21

  • 1王海兰,詹正宇,冯苗,钟陆行.贝伐单抗治疗高级别脑胶质瘤的研究进展[J].中国肿瘤临床,2013,40(16):1001-1004. 被引量:12
  • 2Chen Y,Tachibana O,Oda M,et al.Increased expression of aquaporin 1 in human hemangioblastomas and its correlation with cyst formation[J].J Neurooncol,2006,80(3):219-225.
  • 3Otterbach F,Callies R,Adamzik M,et al.Aquaporin 1(AQP1)expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas[J].Breast Cancer Res Treat,2010,120(1):67-76.
  • 4Kang BW,Kim JG,Lee SJ,et al.Expression of Aquaporin-1,Aquaporin-3,and Aquaporin-5 Correlates with Nodal Metastasis in Colon Cancer[J].Oncology,2015,88(6):1-8.
  • 5Xie Y,Wen X,Jiang Z,et al.Aquaporin 1 and aquaporin 4 are involved in invasion of lung cancer cells[J].Clin Lab,2012,58(1-2):75-80.
  • 6Kalani Y,Filippidis S,Rekate L.Hydrocephalus and aquaporins:the role of aquaporin-1[J].Acta Neurochir,2012,113:51-54.
  • 7Sekine S,Shimada Y,Nagata T,et al.Prognostic significance of aquaporins in human biliary tract carcinoma[J].Oncol Rep,2012,27(6):1741-1747.
  • 8Moon C,Soria C,Jang J,et al.Involvement of aquaporins in colorectal carcinogenesis[J].Oncogene,2003,22(43):6699-6703.
  • 9Yoshida T,Hojo S,Sekine S,et al.Expression of aquaporin-1 is a poor prognostic factor for stage II and III colon cancer[J].Mol Clin Oncol,2013,1(6):953-958.
  • 10Kao C,Armstrong N,Condon B,et al.Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma[J].Cancer,2012,118(11):2952-2961.

二级参考文献24

  • 1Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical re- port: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009[J]. Neuro Oncol, 2012, 14(Suppl 5) : 1-49.
  • 2jo j, Schiff D, Purow B. Angiogenic inhibition in high-grade glio- mas: past, present and future[J]. Expert Rev Neurother, 2012, 12(6): 733-747.
  • 3Liu Y, Zhou Y, Zhang XS, et al. Expression of VEGF and MMP-9 and MR/imaging changes in cerebral glioma[J]. Oncol Lett, 2011, 2 (6):1171-1175.
  • 4LuJF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevaci- zumab in patients with solid tumors[J]. Cancer Chemother Pharma- col, 2008, 62(5):779-786.
  • 5KreisI TiN, Zhang W, Odia Y, et al. A Phase Ⅱ trial of single-agent bevacizumab in patients with recurrent anaplastic glioma[J]. Neuro Oncol, 2011, 13(10):1143-1150.
  • 6Nagane M, Nishikawa R, Narita Y, et al. Phase Ⅱ study of sin- gle-agent bevacizumab n Japanese patients with recurrent malig- nant glioma[J].JpnJ Clin Oncol, 2012, 42(10):887-895.
  • 7Wong ET, Gautam S, Malchow C, et al. Bevacizumab for recur- rent glioblastoma multiforme:a Meta-analysis[J]. J Natl Compr Canc Netw, 2011, 9(4):403-407.
  • 8Perry JR, Bdanger K, Mason WP, et al. Phase Ⅱ trial of continuous dose-intense temozolomide in recurrent malignant glioma: RES- CUE study[J].J Clin Oncol, 2010, 28(12):2051-2057.
  • 9Yung WK, Albright RE, OlsonJ, et al. A phase Ⅱ study of temozolo- mide vs. procarbazine in patients with glioblastoma multiforme at first relapse[J]. BrJ Cancer, 2000, 83 (5):588-593.
  • 10Murray LJ, Bridgewater CH, Levy D. Carboplatin chemotherapy in patients with recurrent high-grade glioma[J]. Clin Oncol(R Coll Ra- dio1), 2011, 23(1):55-61.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部